Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2002-10-31
2010-06-29
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S547000, C514S685000
Reexamination Certificate
active
07745424
ABSTRACT:
The present invention pertains to certain alkane diol derivatives (including, e.g., mono- and di-esters) of the formula R1—O-A-O—R2, wherein: A is a C2-10alkylene group; R1is independently a first hydroxy protecting group (e.g., an ester group); and, R2is independently —H or a second hydroxy protecting group (e.g., an ester group); and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrug thereof, which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit osteoclast survival, formation, and/or activity, and to inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, and the like; and/or conditions associated with inflammation or activation of the immune system.
REFERENCES:
patent: 4077997 (1978-03-01), Blum et al.
patent: 5374707 (1994-12-01), Asrar et al.
patent: 661185 (1951-11-01), None
patent: 663072 (1951-12-01), None
patent: 716877 (1954-10-01), None
patent: 774180 (1956-02-01), None
patent: 774635 (1957-05-01), None
patent: 1 230 840 (1971-05-01), None
patent: 1 272 820 (1972-05-01), None
patent: 1 351 243 (1974-04-01), None
patent: 43-26316 (1968-11-01), None
patent: 02-104562 (1990-04-01), None
patent: 07101922 (1995-04-01), None
patent: WO 94/12463 (1994-06-01), None
patent: WO 01/046135 (2001-06-01), None
Kumar et al., “Hyperbranched polyurethanes with varying spacer segments between the branching points,” Journal of Polymer Science: Part A: Polymer Chemistry, 34, 1996, pp. 839-848.
Kong et a., “Synthesis, Mesomorphism, Isomerization, and Aromatization of Stereoregular Poly{[4-({[6-({[4′-(heptyl)oxy-4-biphenylyl]carbonyl}oxy)-hexyl]oxy}carbonyl)phenyl]acetylene}”, Macromolecules, 1999, 32, pp. 1722-1730.
Armour K.J., et al., 2001, “Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026), ”Arthritis and Rheumatism, vol. 44, No. 9, pp. 2185-2192.
Burgaud, J.L., et al., 1999, “HCT-1026: Treatment of Septic Shock, Treatment of Urinary Incontinence, Treatment of Osteoporosis, Nitric Oxide Donor,”Drugs of the Future, vol. 24, No. 8, pp. 858-861.
Burgaud, J.L., et al., 2002, “Nitric-Oxide Releasing Molecules: A New Class of Drugs with Several Major Indications,”Current Pharmaceutical Design, vol. 8, No. 3, pp. 201-213.
Coxon, F.P., Helfrich, M.H., Van't Hof, R., Sebti, S., Ralston, S.H., Hamilton, A., and Rogers, M.J., 2000, “Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298,”J.Bone Miner.Res., vol. 15, pp. 1467-1476.
Degenhardt and Burdsall, 1986, “Synthesis of Ethenylidenebis(phosphonic acid) and its Tetraalkyl Esters,”J. Org. Chem., vol. 51, pp. 3488-3490.
Del Soldato, P., et al., 1999, “NO-aspirins: a class of new anti-inflammatory and antithrombotic agents,”Trends in Pharmacological Sciences, vol. 20, No. 8, pp. 319-323.
Eberhard and Westheimer, 1965, “Hydrolysis of Phostonates,”J. Amer. Chem. Soc., vol. 87, pp. 253-260.
Herczegh et al, 2002, “Osteoadsorptive Bisphosphonate Derivatives of Fluoroquinolone Antibacterials,”J. Med. Chem., vol. 45, pp. 2338-2341.
Hughes, D.E., Boyce, B.F., 1997, “Apoptosis in bone physiology and disease,”Molecular Pathology, vol. 50, pp. 132-137.
Kong, Y.Y., Yoshida, H., Sarosi, I., Tan, H.L., Timms, E., Capparelli, C., et al, 1999, “OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis,”Nature, vol. 397, pp. 315-323.
Luckman, S.P., Coxon, F.P., Ebetino, F.H., Russell, R.G., and Rogers, M.J., 1998, “Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure- activity relationships in J774 macrophages,”J. Bone Miner.Res., vol. 13, pp. 1668-1678.
MacPherson, H; Noble, B.S.; Ralston, S.H., 1999, “Expression and functional role of nitric oxide synthase isoforms in human osteoblast-like cells,”Bone, vol. 24, pp. 179-185.
Miyaura, N. and Suzuki, A., 1995, “Palladium-catalysed cross-coupling reactions of organoboron compounds,”Chem. Rev., vol. 95, No. 7, pp. 2457-2483.
Mundy, G.R., 1996,Bone Remodelling and its disorders(2nd edition), London: Martin Dunitz.
Nociari, M.N., et al., 1998, “A Novel one-step, highly sensitive fluorimetric assay to evaluate cell-mediated cytotoxicity,”Journal of Immunological Methods, vol. 213, pp. 157-167.
Raisz, L.G., 1988, “Local and systemic factors in the pathogenesis of osteoporosis,”N. Engl. J. Med., vol. 318, pp. 818-828.
Ralston, S.H., 1997, “Science, Medicine and the Future: Osteoporosis,”Br. Med. J., vol. 315, pp. 469-472.
Rodan, G.A., Harada, S., 1997, “The missing bone,”Cell, vol. 89, pp. 677-680.
Takahashi, N.; Akatsu, T.; Udagawa, N.; Sasaki, T.; Yamaguchi, A.; Moseley, J.M.; Martin, T.J.; Suda,T., 1988, “Osteoblastic cells are involved in osteoclast formation,”Endocrinology, vol. 123, pp. 2600-2602, 1988.
van't Hof, R.J., and Ralston, S.H., 1997, “Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity,”J. Bone Miner. Res., vol. 12, pp. 1797-1804.
van't Hof, R.J., et al., 1999, “NO-NSAIDs: A Novel Class of Osteoclast Inhibitors,”Calcified Tissue International, vol. 54, No. Supplement 1, p. S59 (European Symposium on Calcified Tissues, Maastricht, Netherlands, May 7-11, 1999).
Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.I., Yano, K., Fujise, N., et al, 1998, “Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro,”Endocrinology, vol. 139, pp. 1329-1337.
UK Search Report for GB 0126157.7, dated Apr. 23, 2002 (the priority application).
IPER for PCT/GB02/04933, dated Oct. 29, 2003 (the underlying PCT application).
Armour Kenneth J
Greig Iain R
Ralston Stuart H
Van't Hof Robert J
Javanmard Sahar
Nixon & Vanderhye P.C.
Padmanabhan Sreeni
The Univeristy Court of the University of Aberdeen
LandOfFree
Alkane diol derivatives as therapeutic agents for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alkane diol derivatives as therapeutic agents for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alkane diol derivatives as therapeutic agents for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4168068